Amgen to buy Horizon for $28B; Merck, Moderna tout cancer vaccine; FDA approves second KRAS drug; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
We’re taking a hiatus next week as the lights go out at Endpoints for the end-of-year holiday, but will return to your inbox on Dec 31, a Sunday, to recap any news over the next two weeks. Thank you so much for your readership in 2022. Endpoints Weekly began almost two years ago with a blank slate and now has close to 70,000 subscribers. Happy holidays!
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.